Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

a technology of diphenylprop-2-en-1 and derivatives, which is applied in the field of liver disorders using 1, 3diphenylprop-2-en-1 derivatives, can solve the problems of inability to accurately diagnose nafld or nash, inability to do analysis for every single study, and insufficient histological features to distinguish properly nafld or nash

Active Publication Date: 2016-02-25
GENFIT SA
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a new treatment for liver disorders that reduces the plasma levels of certain biomarkers. This treatment involves using a specific type of compound called 1,3-diphenylprop-2-en-1-one derivatives. These compounds have protective properties for the liver and can be used to treat a variety of liver disorders including fibrosis, fatty liver disease, and non-alcoholic steatohepatitis. The technical effect of this patent is providing a new treatment option for liver disorders with a specific compound that has protective properties for the liver.

Problems solved by technology

However, liver biopsy remains the gold standard for evaluating liver fibrosis, but this method of analysis could not be done for every single study due to its invasiveness.
In fact, reliable non-invasive methods are not available to correctly diagnose NAFLD or NASH and even the histological features are not always sufficient to distinguish properly NAFLD or NASH from other conditions such as alcoholic liver disease (Yeh M et al., 2007, Vuppalanchi R and Chalasani N, 2009).
Means for an effective treatment for liver fibrotic diseases, and NAFLD and NASH in particular, are still insufficient.
Recently, studies involving thiazolidinediones (Rosiglitazone and Pioglitazone) have shown that these drugs may improve liver condition but treatment with these drugs is not without undesired effects such as higher risks of congestive cardiac failure and osteoporosis, as well as weight gain with psychological effects on the patient (Dowman J. K et al., 2009; Shiri-Sverdlov R et al., 2006; Neuschwander-Tetri et al., 2003).
Other therapies currently ongoing are seeking to assess in NASH drugs as antioxidants but none of these treatments has yet showed convincing results (Nelson A et al., 2009).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effects of Compounds of General Formula (I) on Liver-Specific Biochemical Indexes

Materials & Methods

[0194]1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Cpd 29 of WO2004 / 005233) has been formulated as hard shell capsules containing 5, 10 or 20 mg of the compound. The compound (80 mg) was administered orally once daily for 28 days. The study has been performed in two parallel groups in double-blind conditions: placebo or Cpd 29 of WO2004 / 005233.

[0195]The tolerability and safety of once-a-day administrations, as well as the efficacy in improving plasma lipids and glucose homeostasis compared with placebo, were evaluated in two pilot trials using relevant biochemical parameters. The data were used to calculate the percentage of change due to the compound when compared to the placebo after 28 days of treatment.

[0196]Results & Conclusions:

[0197]A first pilot, double-blind, placebo controlled, randomized study has been performed in patients suffer...

example 2

Animal Models for Testing Liver-Specific Properties of Compounds of General Formula (I)

Materials & Methods

[0202]Animal Model and Treatment: ob / ob Mice

[0203]Male ob / ob mice (8 weeks of age) were purchased from Charles River (L'Arbresle, France) and were kept on a 12-hour light / dark cycle at a constant temperature of 20±3° C. After a 1 week acclimation, mice were separated in groups of 8 animals selected such that the distribution of their body weight and their 6 hours fasting glycemia determined before the experiment were uniform. Animals were fed a standard chow diet (R03, SAFE) and treated during 26 days with the compounds of interest. Compounds, including the Compound 29 of WO2004005233 (Cpd 29, at 10 or 30 mg / kg / day), Fenofibrate (100 mg / kg / day) and Rosiglitazone (10 mg / kg / day) were administered daily by gavage. Control animals were treated with vehicle only (Carboxymethlycellulose 1%+Tween-80 0.1%). Animals had access to food and water ad libitum.

Animal Model and Treatment: Stud...

example 3

In Vitro / Ex Vivo Models for Testing Liver-Specific Properties of Compounds of General Formula (I)

[0228]Some in vitro / ex vivo models have been established for screening compounds that can have a positive effect on liver fibrosis, oxidative stress, and / or liver inflammation. In fact, a key event in liver fibrosis is the activation of hepatic stellate cells (HSC). After hepatocyte damage, this cell type becomes activated and starts to proliferate (Sato M et al., 2003). Activated HSCs (for example, rat or human HSC isolated from livers or rat HSC-T6 cell line) can be activated and produce excessive amounts of extracellular matrix compounds and inhibitors of matrix degradation. This approach has been used to show the positive effect of compounds such as curcumin (Xu et al., 2003), thiazolidinediones (Miyahara T et al., 2000), or 17beta-estradiol (Liu Q et al., 2004).

[0229]The in vitro / ex vivo models described above allow comparing liver-specific activities of compounds of General Formula...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and / or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

Description

[0001]This application is a continuation of application Ser. No. 14 / 523,191 (published as US 2015-0051145 A1), filed Oct. 24, 2014 (allowed), which is a continuation-in-part of application Ser. No. 14 / 288,482 (issued as U.S. Pat. No. 8,895,619), filed May 28, 2014 (published as US 2014-0309165 A1), which is a continuation of application Ser. No. 13 / 511,170, filed May 22, 2012 (issued as U.S. Pat. No. 8,772,342), which is a U.S. National Phase of International Application No. PCT / EP2010 / 068346, filed 26 Nov. 2010, which designated the U.S. and claims priority to European Patent Application No. 09306146.3, filed 26 Nov. 2009, the entire contents of each of which are hereby incorporated by reference.TECHNICAL FIELD[0002]The invention relates to the use of compounds having hepatoprotective effects in the preparation of pharmaceutical compositions and in methods for treating liver disorders.BACKGROUND[0003]According to the Washington Manual of Medical Therapeutics (31st ed.; 2004; Lippin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/192A61K45/06
CPCA61K45/06A61K31/192A61K9/20A61K31/155A61K31/216A61K31/222A61K31/381A61K31/426A61K38/28C07C321/26A61K2300/00
Inventor DARTEIL, RAPHAELHANF, REMYHUM, DEANDUFOUR, INGRID
Owner GENFIT SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com